Depemokimab is a follow-up to GSK's Nucala (mepolizumab), a once-monthly IL-5 inhibitor approved for severe asthma, CRSwNP, ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

GSK's severe asthma therapy Nucala could find a new lease of life as a treatment for chronic obstructive pulmonary disease ... eosinophilic granulomatosis with polyangiitis, and hypereosinophilic ...

The indication is Nucala’s third in China and comes after prior approvals in eosinophilic asthma and eosinophilic granulomatosis ... Winrevair in the U.K. The pulmonary arterial hypertension ...

Eosinophilic granulomatosis with polyangiitis (EGPA), formerly known ... and 70% of patients have peripheral reticulonodular or consolidative pulmonary opacities on chest x-rays. Pleural effusion and ...

This is not as implausible as seems at first sight; there is compelling evidence that those growing up with early life disadvantage are more likely to be diagnosed with occupational asthma and chronic ...

In fact, one study which infected mice with pulmonary M. tuberculosis and examined their choroid ... B cells are necessary for granuloma formation and in active TB, frequencies are lower and B cells ...

It was also under development for granulomatosis with polyangiitis ... an inhaled formulation of a treprostinil prodrug for pulmonary arterial hypertension (PAH), idiopathic pulmonary fibrosis, and ...

Others, such as eosinophilic granulomatosis with polyangiitis, tend to develop in adults. Symptoms of autoimmune vasculitis can vary depending on the type of condition and which parts of your body ...